Alan Russell
Vermögen: 799 344 $ am 31.05.2026
Vermögen: 799 344 $ am 31.05.2026
Alan Russell is the founder of Edgewise Therapeutics, Inc., founded in 2017, where the title held is Director & Chief Scientific Officer.
Former jobs include Associate Director-Muscle Biology & Therapeutics at Cytokinetics, Inc. from 2002 to 2010, and VP & Head-Muscle Metabolism Discovery Performance at GlaxoSmithKline LLC from 2014 to 2017.
Education includes undergraduate and doctorate degrees from the University of Bath.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 23 400 ( 0,02 % ) | 799 344 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Gründer | 01.01.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Direktor/Vorstandsmitglied | 01.09.2014 |
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01.02.2010 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
University of Bath
University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen